PHILADELPHIA, March 26, 2018 /PRNewswire/ — Enterin Inc., a CNS pharmaceutical company based in Philadelphia and developing novel compounds to treat Parkinson’s disease (PD), autism and schizophrenia, has completed enrollment of a two-stage Phase 2a study of ENT-01 in patients with PD….
